BioLoomics

Executive Summary

BioLoomics is a private biotechnology company based in Boulder, Colorado, founded in 2018. The company develops antibody-based therapeutics and diagnostics by combining computational protein design with high-throughput screening technologies, aiming to accelerate the discovery of novel antibody candidates. Operating at the intersection of antibodies, proteomics, and diagnostics, BioLoomics seeks to address unmet medical needs in areas such as oncology, inflammation, and infectious diseases. Despite its innovative approach, the company remains at an early stage with no disclosed funding rounds, pipeline candidates, or partnerships. The competitive landscape includes established antibody engineering firms and emerging platforms. Key challenges include demonstrating preclinical proof-of-concept, attracting investment, and validating their computational platform against experimental data. Success could position BioLoomics as a versatile antibody discovery engine, but execution risks and capital requirements are significant.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement60% success
• Q4 2026Preclinical Data Release for Lead Antibody Candidate40% success
• 2027Collaboration or Licensing Deal with Pharma Partner30% success